

Predicting treatment response and renal survival in crescentic ANCA associated glemerulonephritis

Weixin Hu, Xia Liu, Yinghua Chen, Huiping Chen, Haitao Zhang, Zhengzhao Liu, Zhihong Liu

National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of medicine, Nanjing, China

Objectives:

- □ Renal damage of crescentic ANCA associated glomerulonephritis (AAGN) is usually aggressive and requires intensive immunosuppressive therapy, but the long-term renal survival is still poor.
- we analyze the factors which may predict treatment response and long-term renal outcome in Chinese patients with crescentic AAGN.

Methods:

- Sixty Chinese patients with renal biopsy-proven crescentic AAGN from 1996 to 2014 were included.
- The patients were classified into renal replacement therapy(RRT) group(n=30) and non-RRT group.
- The patients received glucocorticoids with other immunosuppressant with or without plasmapheresis.
- Treatment response was recorded as good response(GR, defined as the patients got rid of RRT in RRT group, or Scr declined by ≥25% of the baseline value in non-RRT group) and non-response(NR, defined as the patients needed maintenance RRT in RRT group, or Scr declined <25% of the baseline in non-RRT group) at the three months of induction treatment.
- Clinical and histological predictors for treatment response and long-term renal outcome were analyzed.

Results:

Figure 1. Disease's development of all AAGN patients




Table 2. Factors which may effect the long-term renal survival

	Univariate Cox regression		Multivariate Cox regression	
	HR(95%CI)	P	HR(95%CI)	P
age (≥62y)	2.58(1.06~6.33)	0.038		
Needing RRT	5.83(1.96~17.38)	0.002	7.09(2.32~21.65)	0.001
Urine volume(<1500ml/24h)	2.98(2.09~8.15)	0.034		
Upro(≥3.5g/24h)	4.48(1.04~19.26)	0.044	5.90(1.35~25.88)	0.019
Hb(<9. 3g/dl)	3.11(1.05~9.20)	0.041		
Hypoproteinemia(<35g/l)	3.29(1.11~9.77)	0.032		
Scr (>4mg/dl)	8.38(1.95~35.97)	0.004		
High ANCA titer(>230u/ml)	2.84(1.17~6.87)	0.021		
Ratio of crescents(≤30%)	2.41 (1.0~6.0)	0.059		
Ratio of circumferential crescents(>50%)	2.26(0.9~5.62)	0.079		

Figure 2. Treatment Response




Table 1. treatment response in RRT group

	GR group(n=16)	NR group(n=11)	P value
Duration of renal disease, months	1(0.5-1)	1(1-2)	0.028
Upro,g/24h	2.8 (1.5-4.9)	1.65(1.03-3.0)	0.064
Urine volume,ml/24h	1400(1050-1629)	900(355-1300)	0.057
Intensive therapy, n(%)	15(93.8)	6(54.5)	0.016
Crescents/glomeruli, %	26.3(16.2-33.7)	40 (31.6-56)	0.026
Circumferential Crescents/Crescents,%	43.7(25.9-51.5)	73.3 (50-80.7)	0.010
Sclerotic glomeruli, %	9.9(0-14.7)	20(5.6-28)	0.022

■ Non-RRT group: the normal glomerular percentage was markedly higher in GR patients than in NR patients (median:20.4(12.3,29.0)% vs 5.3(2.3,11.5)%, p=0.02), with the normal glomerular percentage >7% being more likely to be GR(HR 13.3, CI 1.7~107.4, p=0.006).

Conclusions:

In crescentic ANCA associated glomerulonephritis, the extent of circumferential crescent and normal golmeruli predicts short-term treatment response, while the need for renal replacement therapy an nephrotic range







